Home > Boards > US Listed > Medical - Drugs > Athenex (ATNX)

Delcath - Pivotal ICC Trials/ Gemcitabine / Athenex

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Leotrader211 Member Profile
 
Followed By 3
Posts 504
Boards Moderated 0
Alias Born 09/18/17
160x600 placeholder
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 5/15/2019 6:16:48 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 8:40:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 7:06:45 AM
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/9/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2019 5:06:58 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/8/2019 4:55:40 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/8/2019 4:02:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2019 8:06:56 AM
Athenex Announces $100 Million Private Placement GlobeNewswire Inc. - 5/6/2019 8:00:00 AM
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire Inc. - 5/3/2019 9:12:18 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/25/2019 4:11:44 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 7:03:49 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:03 AM
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire Inc. - 4/25/2019 7:00:00 AM
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire Inc. - 4/23/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:26:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:23:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:15:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:11:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:28:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:25:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:21:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:11:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2019 4:30:06 PM
Leotrader211   Tuesday, 02/13/18 09:37:08 PM
Re: None
Post # of 14 
Delcath - Pivotal ICC Trials/ Gemcitabine / Athenex

https://www.clinicaltrials.gov/ct2/show/NCT03086993

Delcath (DCTH) for ICC (Intrahepatic Cholangiocarcinoma) trials uses Gemcitabine injection and guess who is bringing it to market .....Athenex (ATNX)

This is a done deal. Jenny you can release the PR, we figured it out through publicly available information.


February 13, 2018
Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced recent product launches from Athenex Pharmaceutical Division (“APD”). These launches highlight the continued portfolio growth with an emphasis on oncology or oncology supportive therapy, a business strategy of Athenex’s commercial business as an effective supplement to its progressing clinical pipeline focused on oncology.
Athenex has brought the following products to market in its 503B (outsourced sterile preparations) and Specialty (finished-dose specialty injectable products) businesses:

503B Products

Epinephrine 2 mg and 4 mg in 250 mL in 0.9% Normal Saline (2 SKUs)
Norepinephrine 4 mg and 8 mg in 250 in 0.9% Normal Saline (2 SKUs)
Specialty Products

Caspofungin Acetate for Injection 50 mg per vial; 70 mg per vial (2 SKUs; vials)
Doxorubicin 5 mL, 25 mL, 100 mL; (3 SKUs; vials)
Etomidate Injection 20 mg per 10 mL; 40 mg per 20 mL; (2 SKUs; vials)
Gemcitabine for Injection 1 mg (1 SKU; vials)
Paclitaxel Injection 30 mg per 5 mL; 100 mg per 16.7 mL; 300 mg per 50 mL; (3 SKUs; vials)

Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APD, commented, “These product launches underscore a continuation of our ongoing commitment to bring needed, quality oncology products to market on both the 503B and Specialty Injectables sides of our business. As part of a broader effort to build our commercial platform and capabilities, we will continue to look for opportunities to bring additional products focused mainly on oncology and oncology supportive care therapies to our customers throughout 2018 as well as generate additional revenue to help fund our clinical programs.”

http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-newsArticle&ID=2332087

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist